Market Commentary - Stock Alert
Infosys, EMS, SJVN, Cipla, Zydus Lifesciences in focus As on : 21-Sep-23  08:55

Infosys: Infosys and NVIDIA announced that they have expanded their strategic collaboration with the aim to help enterprises worldwide, drive productivity gains with generative AI applications and solutions.

EMS: Shares of the company will debut on the bourses today, 21 September 2023. The issue price is Rs 221 per share.

SJVN: The government will offload a 4.92% stake in SJVN at a floor price of Rs 69 per share through a two-day offer for sale. OFS opens for non-retail investors on September 21 and retail investors on September 22.

Cipla: An inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company from 11 to 19th September 2023. On conclusion of the inspection, InvaGen has received 5 inspectional observations in Form 483.

Zydus Lifesciences: The company has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1%. Clindamycin Phosphate Gel is used to treat acne.

Kalpataru Projects International: A meeting of the Executive Committee of the Board of Directors of the Company is scheduled to be held on 25th September 2023, to consider and approve the proposal for the raising of funds by way of issuance of Non-Convertible Debentures on private placement basis.

Powered by Capital Market - Live News